trans-Isoferulic acid
Based on 1 Customer Validation
trans-Isoferulic acid (trans-3-Hydroxy-4-methoxycinnamic acid) is an aromatic acid that exhibits anti-inflammatory activity. trans-Isoferulic acid dephosphorylates PI3K/Akt, suppresses LPS (HY-D1056)-induced NF-κB activation, enhances Nrf2 activity, downregulates iNOS and COX-2 expression, induces HO-1 expression, inhibits NO and PGE2 production, and scavenges hydroperoxyl radical. trans-Isoferulic acid can be used for research of inflammatiory diseases.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 25522-33-2
- Formula: C10H10O4
- Molecular Weight:194.19
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Biological Activity
|
iNOS |
COX-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| B16-BL6 | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| EA.hy 926 | EC50 |
29.3 μM
Compound: 3-OH-4-OCH3-cinnamic acid
|
Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay
Cytoprotective activity against H2O2-induced cytotoxicity in human EAhy926 cells pre-incubated for 24 hrs before H2O2 challenge for 12 hrs by MTT assay
|
10.1039/C4MD00022F |
| HeLa | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| HeLa | IC50 |
≥10 μM
Compound: isoferulic acid
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19278239] |
| HT-1080 | EC50 |
>515 μM
Compound: 10
|
Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 12027739] |
| Oocyte | IC50 |
13.5 μM
Compound: 4-O-Me-Caf-COOH
|
Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique
Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique
|
[PMID: 23682762] |
| RAW264.7 | IC50 |
>50 μM
Compound: 12
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
|
[PMID: 22079762] |
trans-Isoferulic acid (25-200 μM; 1 h pretreatment) does not reduce viability or induce apoptosis in BV2 microglial cells at concentrations ≤150 μM, but causes significant cytotoxicity at 200 μM[1].
trans-Isoferulic acid (50-150 μM; 1 h pretreatment) dose-dependently inhibits LPS-induced NO production in BV2 microglial cells, with complete inhibition at 150 μM[1].
trans-Isoferulic acid (50-150 μM; 1 h pretreatment) dose-dependently inhibits LPS-induced PGE2 production in BV2 microglial cells, with complete inhibition at 150 μM[1].
trans-Isoferulic acid (50-150 μM; 1 h pretreatment) dose-dependently suppresses LPS-induced iNOS and COX-2 mRNA and protein expression in BV2 microglial cells[1].
trans-Isoferulic acid (150 μM; 1 h pretreatment) completely inhibits LPS-induced NF-κB DNA-binding activity in BV2 microglial cells[1].
trans-Isoferulic acid (150 μM; 1 h pretreatment) suppresses LPS-induced phosphorylation of PI3K and Akt in BV2 microglial cells[1].
trans-Isoferulic acid (50-150 μM; 0-24 h) time- and dose-dependently upregulates HO-1 mRNA and protein expression in BV2 microglial cells[1].
trans-Isoferulic acid (50-150 μM; 1 h pretreatment) dose-dependently increases Nrf2 DNA-binding activity in BV2 microglial cells[1].
trans-Isoferulic acid (150 μM; 1 h pretreatment) induced HO-1 expression and subsequent inhibition of LPS-induced NO and PGE2 production in BV2 microglial cells are dependent on Nrf2 activation[1].
trans-isoferulic acid scavenges HOO• radicals via pH-dependent mechanisms[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BV2 microglial cells
-
Concentration:25; 50; 75; 100; 150; 200 μM
-
Incubation Time:24 h (with 1 h pre-incubation before LPS)
-
Result:Showed no cytotoxicity at concentrations ≤150 μM, regardless of LPS treatment.
Detected a statistically significant reduction in cell viability at 200 μM.
-
Cell Line:LPS-stimulated BV2 microglial cells
-
Concentration:50; 100;150 μM
-
Incubation Time:24 h (with 1 h pre-incubation before LPS)
-
Result:Reduced LPS-induced PGE2 levels in a dose-dependent manner.
Dose-dependently suppressed LPS-induced iNOS and COX-2 mRNA.
-
Cell Line:LPS-stimulated BV2 microglial cells
-
Concentration:50; 100; 150 μM
-
Incubation Time:3; 6; 9 h
-
Result:Significantly decreased LPS-induced HO-1 mRNA levels in a dose-dependent manner.
Significantly decreased LPS-induced HO-1 mRNA levels in a time-dependent manner.
Chemical Information
-
CAS No. 25522-33-2
-
Appearance Solid
-
Molecular Weight 194.19
-
Formula C10H10O4
-
Color White to light brown
-
SMILES
O=C(O)/C=C/C1=CC=C(OC)C(O)=C1
-
Synonyms
trans-3-Hydroxy-4-methoxycinnamic acid
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 100 mg/mL (514.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dilshara MG, et al. Downregulation of NO and PGE2 in LPS-stimulated BV2 microglial cells by trans-isoferulic acid via suppression of PI3K/Akt-dependent NF-κB and activation of Nrf2-mediated HO-1. Int Immunopharmacol. 2014;18(1):203-211. [Content Brief]
[2]. Sun KH, et al. A new indole-type alkaloid from the roots of Clematis florida var. plena. Nat Prod Res. 2019 Oct;33(20):2925-2931. [Content Brief]
[3]. Kowalska-Baron A, et al. Theoretical Insight into Antioxidant Mechanisms of Trans-Isoferulic Acid in Aqueous Medium at Different pH. Int J Mol Sci. 2025;26(12):5615. Published 2025 Jun 11. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.1496 mL | 25.7480 mL | 51.4960 mL | 128.7399 mL |
| 5 mM | 1.0299 mL | 5.1496 mL | 10.2992 mL | 25.7480 mL | |
| 10 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL | 12.8740 mL | |
| 15 mM | 0.3433 mL | 1.7165 mL | 3.4331 mL | 8.5827 mL | |
| 20 mM | 0.2575 mL | 1.2874 mL | 2.5748 mL | 6.4370 mL | |
| 25 mM | 0.2060 mL | 1.0299 mL | 2.0598 mL | 5.1496 mL | |
| 30 mM | 0.1717 mL | 0.8583 mL | 1.7165 mL | 4.2913 mL | |
| 40 mM | 0.1287 mL | 0.6437 mL | 1.2874 mL | 3.2185 mL | |
| 50 mM | 0.1030 mL | 0.5150 mL | 1.0299 mL | 2.5748 mL | |
| 60 mM | 0.0858 mL | 0.4291 mL | 0.8583 mL | 2.1457 mL | |
| 80 mM | 0.0644 mL | 0.3218 mL | 0.6437 mL | 1.6092 mL | |
| 100 mM | 0.0515 mL | 0.2575 mL | 0.5150 mL | 1.2874 mL |